Prostate News and Research

RSS

Ferroptosis-based therapy shows promise for advanced prostate cancer treatment

A recent review explores the rapidly expanding field of ferroptosis-based therapy for prostate cancer, presenting ferroptosis as a promising strategy to overcome resistance in advanced and castration-resistant prostate cancer (CRPC).

6 Aug 2026

Study identifies a novel direct drug target for head and neck squamous cell carcinoma

Chemotherapy remains a cornerstone of treatment for head and neck cancers, the seventh-most common cancer type worldwide.

6 Aug 2026

Older men’s sexual priorities extend well beyond erectile function

A web-based survey of 6,000 Japanese men aged 50 or older found that sexual arousal was the function they most wanted to preserve, while erection became more highly valued as erectile function worsened. Erection showed the earliest age-related decline pattern, whereas ejaculation was the function most often reported as lost in older age.

6 Aug 2026

HMGCR emerges as a promising target for precision cancer therapies

A growing body of evidence is reshaping how scientists and clinicians understand the role of cancer metabolism, placing the enzyme HMGCR at the center of a rapidly evolving therapeutic landscape.

5 Aug 2026

Tadalafil may increase glaucoma risk in men with enlarged prostates

An erectile dysfunction drug that is also used to treat symptoms like sudden urgency and frequency, which are associated with an enlarged prostate in men, may heighten the risk of the serious eye condition, glaucoma, finds a large comparative study published online in the British Journal of Ophthalmology.

4 Aug 2026

AI tool helps customize radiopharmaceutical therapy dosing

Radiopharmaceutical therapy (RPT) has made great strides over the last 50 years, having only recently received FDA approval to treat prostate cancer. But despite the progress-and billions of dollars of industry investments-one area that has lagged behind is dosing, which is still one-size-fits-all.

4 Aug 2026

UCLA researchers find strategy to improve prostate cancer therapies

UCLA researchers have identified a promising strategy to make a new class of targeted cancer therapies more effective against one of the deadliest forms of prostate cancer, potentially overcoming treatment resistance that has limited their success.

3 Aug 2026

Combination therapy improves progression-free survival in dMMR/MSI-H metastatic colorectal cancer

Patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer experienced a 58% reduction in the risk of disease progression or death when treated with atezolizumab plus modified FOLFOX6 and bevacizumab compared with atezolizumab alone, according to results from the NRG-GI004/SWOG S1610 COMMIT trial published recently in the Journal of Clinical Oncology.

29 Jul 2026

DNA enhancer hubs control cancer genes in prostate tumors

Enhancers are pieces of DNA that act like switches, regulating when genes are turned on and off and how strongly they are activated.

22 Jul 2026

Common heart risk calculators effectively predict certain types of cancer

Risk calculators that doctors use to estimate a person's risk of a heart attack or stroke work about as well for predicting certain cancers, according to a new study by UCL (University College London) researchers.

21 Jul 2026

New tumor organoids strengthen precision oncology research

Significant advances have been made in the development of patient-derived tumor "organoids" for preclinical research, in two new studies led by Weill Cornell Medicine investigators.

20 Jul 2026

New ctDNA blood test improves personalized prostate cancer treatment

A noninvasive DNA blood test can identify metastatic castration-resistant prostate cancer (mCRPC) patients who are most likely to benefit from 223Ra radiopharmaceutical therapy and monitor their progress throughout treatment, according to new research published in the July issue of The Journal of Nuclear Medicine.

17 Jul 2026

New guideline offers recommendations for testosterone replacement therapy use

The Society's Clinical Practice Guideline on testosterone replacement therapy in men with hypogonadism offers recommendations on appropriate testing and prescribing practices.

16 Jul 2026

Weill Cornell Medicine receives DoD grant to target triple-negative breast cancer

Weill Cornell Medicine has received a $2.5 million, three-year grant from the Department of Defense (DoD) to develop therapies with fewer side effects for triple-negative breast cancer, one of the most aggressive and difficult-to-treat breast cancers.

16 Jul 2026

Breast and prostate cancer survival worsens with metabolic syndrome

A SEER-Medicare analysis of more than 200,000 adults aged 66 and older found that metabolic syndrome was associated with about twice the adjusted hazard of death from any cause after breast or prostate cancer. The condition was also linked to higher cancer-specific, cardiovascular-specific, and liver-failure-specific mortality, although the observational design prevents causal conclusions.

14 Jul 2026

High physician knowledge scores linked to lower healthcare costs

Patients whose physicians scored higher in the first year of the American Board of Internal Medicine's (ABIM) Internal Medicine Longitudinal Knowledge Assessment (LKA) were significantly less likely to receive low-value healthcare services, which cumulatively cost the U.S. healthcare system an estimated $100 billion each year.

13 Jul 2026

New generation approaches revive BET protein inhibitors in solid tumors

BET proteins, especially BRD4, drive oncogenic transcription in solid tumours. First‑generation inhibitors (JQ1, molibresib, birabresib) showed preclinical promise but failed clinically due to modest efficacy, dose‑limiting thrombocytopenia, and resistance (isoform switching, compensatory PI3K/AKT/WNT signalling).

11 Jul 2026